Trial Profile
Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs Ibodutant (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Acronyms IRIS-2
- Sponsors Menarini
- 15 Apr 2016 Results published in the Gut
- 21 May 2013 Results presented at Digestive Disease Week 2013.
- 06 Oct 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.